Production (Stage)
OS Therapies Incorporated
OSTX
$1.67
$0.042.45%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.40M | 3.97M | 2.02M | 957.30K | 1.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.18M | 6.81M | 5.00M | 3.19M | 3.92M |
| Operating Income | -11.18M | -6.81M | -5.00M | -3.19M | -3.92M |
| Income Before Tax | -11.30M | -8.88M | -7.36M | -6.46M | -7.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.30 | -8.88 | -7.36 | -6.46 | -7.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.30M | -8.88M | -7.36M | -6.46M | -7.40M |
| EBIT | -11.18M | -6.81M | -5.00M | -3.19M | -3.92M |
| EBITDA | -11.18M | -6.81M | -5.00M | -3.18M | -3.92M |
| EPS Basic | -0.85 | -0.92 | -0.83 | -1.02 | -1.24 |
| Normalized Basic EPS | -0.48 | -0.51 | -0.51 | -0.63 | -0.76 |
| EPS Diluted | -0.85 | -0.92 | -0.83 | -1.02 | -1.24 |
| Normalized Diluted EPS | -0.48 | -0.51 | -0.51 | -0.63 | -0.76 |
| Average Basic Shares Outstanding | 64.90M | 49.64M | 38.56M | 28.00M | 27.35M |
| Average Diluted Shares Outstanding | 64.90M | 49.64M | 38.56M | 28.00M | 27.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |